Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics reported a strong financial position with $249.3 million in cash as of March 31, 2020, up from $101.3 million at year-end 2019, sufficient to fund operations through 2021. Despite COVID-19 challenges, the company anticipates no delays in clinical timelines and expects six data readouts over the next 18 months. Significant advancements include two Phase 3 trials of roflumilast cream for plaque psoriasis, with topline data expected in 2021. The net loss for Q1 2020 stood at $28 million, compared to $6.7 million in Q1 2019.